SCHEMBL4213227

SCHEMBL4213227

CC(C)(C)OC(=O)c1ccc(CCc2ccccc2)cc1Nc1ccc(F)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.47
▸ POLB P06746 1/20 0.47
▸ ULK1 O75385 1/20 0.41
▸ PLA2G2A P14555 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ MAPK14 Q16539 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ ATM Q13315 1/20 0.39
▸ GAA P10253 1/20 0.38
▸ PPARG P37231 2/20 0.38
▸ PPARA Q07869 2/20 0.38
▸ HTT P42858 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ FFAR4 Q5NUL3 1/20 0.38
▸ PPIA P62937 1/20 0.37
▸ MAP2K1 Q02750 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4217327 0.90 RAB9A (0.42) RAB9APOLBPLA2G2AMEN1KMT2A
SCHEMBL4215772 0.87 SIRT2 (0.45) PLA2G2AALDH1A1MEN1KMT2AGAA
SCHEMBL4223424 0.84 RAB9A (0.55) RAB9APOLBULK1ALDH1A1MEN1
SCHEMBL4221179 0.82 POLB (0.46) POLBALDH1A1MEN1KMT2AATM
SCHEMBL4219791 0.80 ADRA1A (0.39) MEN1KMT2A
SCHEMBL4221441 0.79 SIRT2 (0.46) MEN1KMT2AFFAR4
SCHEMBL4220608 0.78 ADRA1A (0.46) POLBALDH1A1ATMGAAL3MBTL1
SCHEMBL4222218 0.78 P2RX7 (0.46) MEN1KMT2AMAPK1
SCHEMBL4210580 0.78 SIRT2 (0.43) ALDH1A1MEN1KMT2AGAAPPARA
SCHEMBL4210962 0.77 KDM4E (0.47) RAB9APOLBALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 — — US disclosed
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 — — US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 — — EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 — — US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 RAB9A 2262/4885POLB 3706/4885ULK1 3688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback